Form 4: Processa Pharmaceuticals CAO Increases Equity Stake
Statement of Changes in Beneficial Ownership
Chief Administrative Officer Wendy Guy acquired 1,583 shares of Processa Pharmaceuticals common stock at $2.97 per share.
Summary
- Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc., purchased 1,583 shares of common stock on May 15, 2026.
- The shares were acquired at a price of $2.97 per share.
- Following the transaction, the reporting person directly owns 8,011 shares.
- The filing includes a correction to a previous Form 4 regarding a transaction on April 30, 2026, adjusting the price per share to $2.71 and reducing the previously reported purchase amount by 13 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; while insider buying is generally positive, the necessity of an amendment for previous reporting errors offsets the sentiment.
Positives
- Insider confidence is demonstrated through the direct purchase of company stock by a senior executive.
Negatives
- The filing required an amendment to correct previous reporting errors regarding share counts and pricing.
Risks
- General market risks associated with pharmaceutical development and equity volatility.
Future Outlook
No forward-looking guidance or strategic outlook provided in this disclosure.
Industry Context
StockSavvy.ai notes that insider buying in small-cap biotech firms is often viewed as a positive signal of management alignment with shareholder interests, though it remains a routine disclosure of personal financial activity.
Comparison to Industry Standards
- Insider transactions are standard regulatory requirements for public companies.
- The correction of previous filing errors is a common administrative process in corporate governance.
Related Party Transactions
- The reporting person maintains an indirect interest in 333 shares held by CorLyst, LLC.
Stakeholder Impact
- Minor impact; provides transparency regarding executive share ownership.
Next Steps
- Continued monitoring of future insider transaction filings.
Key Dates
| Date | Description |
|---|---|
| 04/30/2026 | Date of original transaction requiring correction. |
| 05/15/2026 | Date of the reported stock purchase. |
| 05/19/2026 | Date the Form 4 was filed. |
Keywords
Processa Pharmaceuticals, PCSA, Insider Trading, Form 4, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.